BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34035409)

  • 1. Base-edited CAR T cells for combinational therapy against T cell malignancies.
    Georgiadis C; Rasaiyaah J; Gkazi SA; Preece R; Etuk A; Christi A; Qasim W
    Leukemia; 2021 Dec; 35(12):3466-3481. PubMed ID: 34035409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
    Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy.
    Rasaiyaah J; Georgiadis C; Preece R; Mock U; Qasim W
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
    Xie L; Ma L; Liu S; Chang L; Wen F
    Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
    Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
    Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
    Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
    Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
    Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
    Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies.
    Zhang C; Palashati H; Rong Z; Lin N; Shen L; Liu Y; Li S; Yu B; Yang W; Lu Z
    Mol Cancer; 2020 Nov; 19(1):162. PubMed ID: 33218364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
    Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
    Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
    Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
    Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells.
    Xie L; Gu R; Yang X; Qiu S; Xu Y; Mou J; Wang Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2023 Dec; 34(23-24):1257-1272. PubMed ID: 37861302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
    J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy.
    Kim MY; Cooper ML; Jacobs MT; Ritchey JK; Hollaway J; Fehniger TA; DiPersio JF
    JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry.
    Ginaldi L; Matutes E; Farahat N; De Martinis M; Morilla R; Catovsky D
    Br J Haematol; 1996 Jun; 93(4):921-7. PubMed ID: 8703826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Lu P; Liu Y; Yang J; Zhang X; Yang X; Wang H; Wang L; Wang Q; Jin D; Li J; Huang X
    Blood; 2022 Jul; 140(4):321-334. PubMed ID: 35500125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lineage determination of CD7+ CD5- CD2- and CD7+ CD5+ CD2- lymphoblasts: studies on phenotype, genotype, and gene expression of myeloperoxidase, CD3 epsilon, and CD3 delta.
    Yoneda N; Tatsumi E; Teshigawara K; Nagata S; Nagano T; Kishimoto Y; Kimura T; Yasunaga K; Yamaguchi N
    Am J Hematol; 1994 Apr; 45(4):310-20. PubMed ID: 7513945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
    Chen D; You F; Xiang S; Wang Y; Li Y; Meng H; An G; Zhang T; Li Z; Jiang L; Wu H; Sheng B; Zhang B; Yang L
    Am J Cancer Res; 2021; 11(11):5263-5281. PubMed ID: 34873460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.
    Golubovskaya VM; Berahovich R; Xu Q; Zhou H; Xu S; Guan J; Harto H; Li L; Wu L
    Front Biosci (Landmark Ed); 2018 Jun; 23(12):2245-2254. PubMed ID: 29772559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.